Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 7809
  • Home
  • Print this page
  • Email this page

    Article Cited by others


Bevacizumab: Off-label use in ophthalmology

Grisanti Salvatore, Ziemssen Focke

Year : 2007| Volume: 55| Issue : 6 | Page no: 417-420

   This article has been cited by
1 Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy
K Ghasemi Falavarjani,M Hashemi,M Modarres,A Hadavand Khani
Eye. 2014;
[Pubmed]  [Google Scholar] [DOI]
2 Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration
Ciro Costagliola,Luca Agnifili,Barbara Arcidiacono,Sarah Duse,Vincenzo Fasanella,Rodolfo Mastropasqua,Marco Verolino,Francesco Semeraro
Expert Opinion on Biological Therapy. 2012; 12(10): 1299
[Pubmed]  [Google Scholar] [DOI]
3 Perioperative use of bevacizumab in vitrectomy for proliferative diabetic retinopathy: A literature review
Falavarjani, K.G., Modarres, M.
Iranian Journal of Ophthalmology. 2010; 22(2): 5-12
[Pubmed]  [Google Scholar]
4 Short-term response of macular oedema to intravitreal bevacizumab
Welch, D.E., Elmariah, H., Peden, M.C., Adams, S.G., Ratnakaram, R., Kaushal, S.
British Journal of Ophthalmology. 2009; 93(8): 1033-1036
[Pubmed]  [Google Scholar]
5 Bevacizumab for ocular neovascular diseases: A systematic review
Andriolo, R.B., Puga, M.E., Beifort Jr., R., Atallah, .N.
Sao Paulo Medical Journal. 2009; 127(2): 84-91
[Pubmed]  [Google Scholar]


Read this article